Jazz plots mas­sive growth for UK cannabi­noid op­er­a­tions

One year af­ter Jazz Phar­ma­ceu­ti­cals ac­quired GW Phar­ma and its cannabi­noid drug Epid­i­olex for epilep­sy, the com­pa­ny is pump­ing $100 mil­lion in­to a new man­u­fac­tur­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER